Everest医药通过在亚洲获得VIS-101的许可协议，扩展到眼科领域Everest Medicines Expands into Ophthalmology with Licensing Agreement for VIS-101 in Asia

动脉网

11/03

Everest Medicines Expands into Ophthalmology with Licensing Agreement for VIS-101 in Asia依生医药通过与VIS-101在亚洲的许可协议进军眼科领域November 03, 20252025年11月3日Everest Medicines has announced its entry into the ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2580153782"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580153782\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580153782?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-11-03 18:31","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2580153782","market":"hk","top_or_hot":-1,"title":"Everest医药通过在亚洲获得VIS-101的许可协议，扩展到眼科领域Everest Medicines Expands into Ophthalmology with Licensing Agreement for VIS-101 in Asia","media":"动脉网","content":"<div>\n<p>Everest Medicines Expands into Ophthalmology with Licensing Agreement for VIS-101 in Asia依生医药通过与VIS-101在亚洲的许可协议进军眼科领域November 03, 20252025年11月3日Everest Medicines has announced its entry into the ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110318341494ebec21&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Everest医药通过在亚洲获得VIS-101的许可协议，扩展到眼科领域Everest Medicines Expands into Ophthalmology with Licensing Agreement for VIS-101 in Asia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEverest医药通过在亚洲获得VIS-101的许可协议，扩展到眼科领域Everest Medicines Expands into Ophthalmology with Licensing Agreement for VIS-101 in Asia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-03 18:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110318341494ebec21&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Everest Medicines Expands into Ophthalmology with Licensing Agreement for VIS-101 in Asia依生医药通过与VIS-101在亚洲的许可协议进军眼科领域November 03, 20252025年11月3日Everest Medicines has announced its entry into the ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110318341494ebec21&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110318341494ebec21&s=b","article_id":"2580153782","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110318341494ebec21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2580153782","pubTimestamp":1762165860,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Strategic Entry into Ophthalmology战略性进入眼科领域With this licensing agreement, Everest Medicines officially expands its therapeutic portfolio into the ophthalmology sector. The collaboration with Visara introduces a promising retinal disease candidate, VIS-101, into Everest's pipeline, marking a significant milestone in the company's growth strategy..根据该许可协议，云顶新耀正式将其治疗领域扩大至眼科。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01952":"云顶新耀","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","09939":"开拓药业-B","BK1583":"高瓴概念"},"translate_title":"Everest Pharmaceuticals expands into ophthalmology by obtaining licensing agreement for VIS-101 in Asia Everest Medicines Expands into Ophthalmology with Licensing Agreement for VIS-101 in Asia","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":0.9,"09939":1.5},"content_text":"Everest Medicines Expands into Ophthalmology with Licensing Agreement for VIS-101 in Asia依生医药通过与VIS-101在亚洲的许可协议进军眼科领域November 03, 20252025年11月3日Everest Medicines has announced its entry into the ophthalmology field through an exclusive licensing agreement with Visara, a subsidiary of NovaBridge Biosciences. The deal grants Everest rights to develop, manufacture, and commercialize the retinal disease candidate VIS-101 in Greater China, Singapore, South Korea, and select Southeast Asian countries..Everest医药宣布通过与NovaBridge生物科学子公司Visara的独家许可协议进入眼科领域。该协议授予Everest在大中华区、新加坡、韩国及部分东南亚国家开发、生产和商业化视网膜疾病候选药物VIS-101的权利。Strategic Entry into Ophthalmology战略性进入眼科领域With this licensing agreement, Everest Medicines officially expands its therapeutic portfolio into the ophthalmology sector. The collaboration with Visara introduces a promising retinal disease candidate, VIS-101, into Everest's pipeline, marking a significant milestone in the company's growth strategy..根据该许可协议，云顶新耀正式将其治疗领域扩大至眼科。与Visara的合作将一种前景广阔的视网膜疾病候选药物VIS-101引入云顶新耀的研发管线，标志着公司增长战略中的重要里程碑。About VIS-101: A Novel Bifunctional Biologic关于VIS-101：一种新型双功能生物制品VIS-101 is a first-in-class bifunctional biologic therapy that targets both VEGF-A and ANG-2. This dual-targeting approach is designed to deliver improved potency and extended therapeutic durability compared to existing treatment options for wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO)..VIS-101 是一种首创的双功能生物疗法，靶向 VEGF-A 和 ANG-2。这种双重靶向方法旨在提供比现有的湿性年龄相关性黄斑变性 (AMD)、糖尿病性黄斑水肿 (DME) 和视网膜静脉阻塞 (RVO) 治疗方案更高的效力和更长的治疗持久性。VIS-101 has already completed initial safety and dose-escalation studies in both the United States and China. It is currently undergoing a randomized, dose-ranging Phase 2 clinical trial in China and is expected to be Phase 3-ready by 2026.VIS-101 已经在美国和中国完成了初步的安全性和剂量递增研究。目前，它正在中国进行一项随机、剂量范围的二期临床试验，并预计将在 2026 年前进入三期临床试验阶段。Licensing Terms and Financial Structure许可条款和财务结构Under the terms of the agreement:根据协议条款：• Everest Medicines will make an upfront payment of $7 million (approximately RMB49.7 million)• Everest Medicines将支付700万美元（约合人民币4970万元）的首付款• It will also reimburse up to $3.4 million (RMB24.0 million) in prior development expenses• 它还将报销高达340万美元（人民币2400万元）的先前开发费用• The company is committed to milestone payments of up to $89 million (approximately RMB632 million)• 该公司承诺支付高达8900万美元（约合人民币6.32亿元）的里程碑款项。• Additionally, Everest will pay tiered royalties based on future net sales• 此外，Everest 将根据未来的净销售额支付分层版税Executive Perspective高管视角“We are pleased to collaborate with Visara,” stated Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “This partnership brings a highly differentiated and commercially attractive asset to Everest’s late-stage pipeline and marks our entry into ophthalmology, a therapeutically attractive area with significant unmet medical needs.“我们很高兴与Visara合作，”Everest医药公司的首席执行官罗杰斯·永清·罗表示。“这次合作为Everest的后期研发管线带来了一个高度差异化且商业吸引力强的资产，并标志着我们进入了眼科领域，这是一个具有显著未满足医疗需求的治疗领域。”Leveraging Everest’s clinical development and commercialization expertise, we look forward to advancing VIS-101, a potential best-in-class bifunctional antibody, towards commercialization in China and across Asia.”.利用Everest公司在临床开发和商业化方面的专业知识，我们期待推进VIS-101（一种潜在的同类最优双功能抗体）在中国乃至整个亚洲的商业化进程。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}